Abstracts tagged "T Cell"

Abstract Number: 2463 • ACR Convergence 2023
Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
Jule Taubmann¹, Johannes Knitza², Fabian Müller³, Sebastian Boeltz¹, Simon Voelkl⁴, Michael Aigner⁴, Arnd Kleyer⁵, Ioanna Minnopoulou¹, Regina Gary⁴, Sascha kretschmann⁴, Andreas Mackensen⁴ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ³Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Antisynthetase syndrome (ASS) can be very severe affecting the lungs, the skin and the joints next to the muscles. ASS can take a refractory…
Abstract Number: 0071 • ACR Convergence 2023
Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease
Viktoria Hennings, Anneke van Dijk, Andri Lemarquis, Christina Lundqvist and Olov Ekwall, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Females exhibit a more robust response to both self- and non-self-antigens than males which manifests as higher prevalence of autoimmune disease, eg. rheumatic diseases,…
Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
Abstract Number: 0800 • ACR Convergence 2023
CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Jose Morales², Yuki Sato², Chenyao Wang², Matthew Koster³, Kenneth Warrington³, Gerald J. Berry⁴, Jorg Goronzy³ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of…
Abstract Number: 1382 • ACR Convergence 2023
Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Qinghong Liu¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by systemic involvement and lacks effective treatment options. The Janus kinase (JAK) pathway plays a…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0072 • ACR Convergence 2023
Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Marie Naingeon¹, Samuel Bitoun², Matthieu roulleaux Dugage¹, Caroline de Oliveira¹, Caroline Berthot¹, Xavier Mariette³, Nathalie Chaput¹ and Gaetane Nocturne⁴, ¹LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, ²CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ³Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
Abstract Number: 0092 • ACR Convergence 2023
Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
Abstract Number: 0803 • ACR Convergence 2023
IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome
Matthew Eremita¹, Omar Geier², Joyce Hui-Yuen¹ and Matthew Taylor³, ¹Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, ³Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 0073 • ACR Convergence 2023
PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
Sofie Rask¹, Christian Andersen², Malene Hvid¹, Kim Ravnskjær², Bent Deleuran¹ and Stinne Greisen³, ¹Aarhus University, Aarhus, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Programmed death 1 (PD-1) is an immune checkpoint receptor expressed by activated T cells, and of major importance in maintaining peripheral tolerance. Expression of…
Abstract Number: 0094 • ACR Convergence 2023
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Helena Jonsson¹, Carlos Donado², Erin Theisen², Dominique Jones¹, Aparna Nathan³, Fan Zhang⁴, Accelerating Medicines Partnership (AMP): RA/SLE¹, Soumya Raychaudhuri¹ and Michael Brenner², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴University of Colorado, Aurora, CO
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
Abstract Number: 0804 • ACR Convergence 2023
Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Leah M. Huey¹, Emily Vance¹, Holly L. Rosenzweig², Bryce Binstadt³ and Ruth J. Napier², ¹Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, VA Portland Health Care System, Portland, OR, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Microbial sensing molecule nucleotide-binding oligomerization-domain containing protein 2 (NOD2) is expressed by CD4+ T cells and plays a novel T cell-intrinsic role within CD4+…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…

« Previous Page
1
…
6
7
8
9
10
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].